Delivery is key: lessons learnt from developing splice‐switching antisense therapies - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue EMBO Molecular Medicine Année : 2017

Delivery is key: lessons learnt from developing splice‐switching antisense therapies

Résumé

The use of splice-switching antisense therapy is highly promising, with a wealth of pre-clinical data and numerous clinical trials ongoing. Nevertheless, its potential to treat a variety of disorders has yet to be realized. The main obstacle impeding the clinical translation of this approach is the relatively poor delivery of antisense oligonucleotides to target tissues after systemic delivery. We are a group of researchers closely involved in the development of these therapies and would like to communicate our discussions concerning the validity of standard methodologies currently used in their pre-clinical development, the gaps in current knowledge and the pertinent challenges facing the field. We therefore make recommendations in order to focus future research efforts and facilitate a wider application of therapeutic antisense oligonucleotides.
Fichier principal
Vignette du fichier
EMBO Mol Med - 2017 - Godfrey - Delivery is key lessons learnt from developing splice‐switching antisense therapies.pdf (1.55 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03828351 , version 1 (25-10-2022)

Identifiants

Citer

Caroline Godfrey, Lourdes Desviat, Bård Smedsrød, France Piétri-Rouxel, Michela Denti, et al.. Delivery is key: lessons learnt from developing splice‐switching antisense therapies. EMBO Molecular Medicine, 2017, 9 (5), pp.545-557. ⟨10.15252/emmm.201607199⟩. ⟨hal-03828351⟩
12 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More